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http://www.ro-journal.com/content/7/1/193RESEARCH Open AccessDefinitive radiotherapy for early (T1-T2) Glottic
Squamous cell carcinoma: a 20 year Cleveland
clinic experience
Mohammad K Khan1*, Shlomo A Koyfman2, Grant K Hunter2, Chandana A Reddy2 and Jerrold P Saxton2Abstract
Purpose: To report our 20 yr experience of definitive radiotherapy for early glottic squamous cell carcinoma (SCC).
Methods and materials: Radiation records of 141 patients were retrospectively evaluated for patient, tumor, and
treatment characteristics. Cox proportional hazard models were used to perform univariate (UVA) and multivariate
analyses (MVA). Cause specific survival (CSS) and overall survival (OS) were plotted using cumulative incidence and
Kaplan-Meir curves, respectively.
Results: Of the 91% patients that presented with impaired voice, 73% noted significant improvement. Chronic
laryngeal edema and dysphagia were noted in 18% and 7%, respectively. The five year LC was 94% (T1a), 83% (T1b),
87% (T2a), 65% (T2b); the ten year LC was 89% (T1a), 83% (T1b), 87% (T2a), and 53% (T2b). The cumulative
incidence of death due to larynx cancer at 10 yrs was 5.5%, respectively. On MVA, T-stage, heavy alcohol
consumption during treatment, and used of weighted fields were predictive for poor outcome (p < 0.05). The five
year CSS and OS was 95.9% and 76.8%, respectively.
Conclusions: Definitive radiotherapy provides excellent LC and CSS for early glottis carcinoma, with excellent voice
preservation and minimal long term toxicity. Alternative management strategies should be pursued for T2b glottis
carcinomas.
Keywords: Glottic carcinoma, Larynx, Outcome, Radiotherapy, Squamous cell, CarcinomaIntroduction
Several institutions have reported long term outcomes of
patients with T1-2N0 SCC of the glottis treated with de-
finitive radiotherapy[1-10]. The five-year local control
(LC) rates have ranged from 82-94% for T1a, 80-93% for
T1b, 62-94% for T2a, and 23-73% for T2b. We report
our first 20 year institutional outcome, and identify pa-
tient, tumor, and treatment related factors associated
with inferior outcomes.Methods and materials
We obtained institutional review board (IRB) approval
to retrospectively review the charts of all patients treated
with definitive radiotherapy at the Cleveland Clinic be-
tween 1986–2006. All patients had biopsy-proven* Correspondence: drkhurram2000@gmail.com
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reproduction in any medium, provided the orinvasive SCC of the glottis, staged T1 or T2 with nega-
tive lymph node disease, and had received an uninter-
rupted course of radiotherapy. Patients were excluded if
they previously had major surgery of the neck or the
glottis, had a synchronous primary, or had received
chemotherapy. Minor surgery (stripping for squamous
cell carcinoma in-situ (SCIS) or minor cordotomy) was
allowed. The AJCC 6th edition [11] was used to stage all
patients, but with further sub-classification of T2
patients. Patients were staged as follows: T1 included
tumor confined to a single vocal cord (T1a) or both
vocal cords (T1b) with normal vocal cord mobility; T2
included tumor with supra- or subglottic extension and
further subdivided into T2a (without) or T2b (with)
impaired vocal cord mobility.
All patients were treated with radiotherapy alone using
either a unilateral field or a weighted opposed lateral
field technique (Figure 1A). Standard field borders wered. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Example of Arrangement & Weighting of Fields (1A)
and Comparison of Non- Bulky vs. Bulky Tumor (1B).
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thyroid notch; 2) inferior: bottom of cricoid cartilage; 3)
posterior: 1 cm posterior to the thyroid cartilage but an-
terior to the vertebral body; 4) anterior: 1 cm anterior to
the skin of the neck (“flash”). Most patients were treated
using 5500 cGy (range 4400–6940 cGy) in 25 fractions
of 220 cGy per fraction (range 180–225 cGy) using a lar-
ger field followed by a boost to a smaller volume “cone
down” of 1320 cGy (range 600–2520 cGy) using 220
cGy per fraction (range 180–225 cGy) for a total dose of
6820 cGy (range 6300–7264) to the tumor. Higher radi-
ation doses were reserved for patients with more bulky
T2 tumors. Most patients underwent a cone down after
5500cGy where the posterior border was placed immedi-
ately posterior to the arytenoids, unless tumor extended
to this region. Unilateral fields were used for unilateral
and well localized tumors. Bilateral fields were used for
all other tumors using one of three techniques depend-
ing on the relative distribution of the tumor across bothvocal cords: equally weighted, weighted 2:1, or weighted
3:2. The neck nodes were treated only in cases where
there was significant supragottic or sublgottic extension
suggesting increased likelihood for subclinical nodal in-
volvement. This methodology has been kept consistent
over the 20 yrs of this study, and is part of the routine
practice at our institution.
All statistical computations were performed using SAS
version 9.2 (SAS Institute Inc., Cary, NC software. Local
control (LC) and overall survival (OS) were plotted using
the Kaplan-Meier method. The log-rank test was used to
detect statistically significant differences among survival
curves. Cause specific survival (CSS) was calculated
using the cumulative incidence method. UVA and MVA
analyses were performed via Cox regression analysis for
the endpoint LC. The following parameters were
included in the UVA: age, gender, race, smoking status,
heavy alcohol consumption, tumor bulk (amount of cord
involved), grade, histology, T-stage (T2 vs T1 and T2b vs
all T1/T2a), anterior commissure involvement, supra-
glottic/subglottic extension, daily dose ≤2 Gy, total dose
≤66 Gy, field weighting (unilateral vs. bilateral equally
weighted vs. bilateral unequally weighted), and total
treatment time. Tumor bulk was modeled as a continu-
ous variable and classified as involvement of > 2/3 of a
cord involved by tumor (Figure 1B). Anterior commis-
sure involvement with extension beyond 1/3 of each
cord was categorized as a bulky tumor (Figure 1B). This
classification of tumor bulk is identical to that published
by Reddy et al. [12] Total dose and treatment time were
also modeled as continuous variables. Factors that were
significant (p-value <0.05) in the UVA were then
included in a MVA. Quality of life variables that were
assessed to determine acute and late toxicity post radi-
ation included: patient and physician reported voice
quality pre- and post treatment, physician reported la-
ryngeal edema as noted on direct laryngoscopy, patient
reported symptomatic dysphagia requiring dilatations,
pre and post treatment trismus, the need for salvage sur-
geries, and the patterns of failure.
Results
Patient, tumor and treatment related characteristics are
depicted in Table 1, along with their association with
local control on UVA. The mean follow-up time was 5.6
years. The mean age of the patients was 67 years. The
median dose was 6820 cGy delivered at 212 cGy per
fraction in 32 fractions over 45 days. On UVA, heavy al-
cohol use during radiation (p = .02), anterior commis-
sure involvement (p = .05), stage (p = .02), total radiation
dose (p= 0.04), subglottic extension (p = .05), and field
weighting (p =0.01) were predictive for poor local control.
On MVA, concurrent heavy alcohol usage (p < 0.01), stage
T2b (p=.02), and field weighting (p = .025) were significant
Table 1 Patient (n – 141) Characteristics and Univariate
Analysis for Impact on Local Control
Characteristic # of Patients
(range or %)
p value











Current 32 (22.7%) 0.5568
Unknown 5 (3.5%)
Heavy Alchohol Use 0.0630
Never (Reference) 89 (63.1%)
Former 21 (14.9%) 0.8836




Non Involved 52 (36.9%)
Unknown 18 (12.8%)
Tumor Bulk 0.6386
Bulky 55 ( 39%)
Non bulky 86 ( 61%)
Hemoglobin (g/dL) 14.2
Grade 0.6614
Well (Reference) 43 (30.5%)
Moderate 57 (40.4%) 0.7192
Poor 14 (10%) 0.3646
Unknown 27 (19.1%)
Stage (T2b vs T1a/b/2a) 0.0205
1a 65 ( 46%) 0.0033
1b 21 (14.9%) 0.1766
2a 29 (20.6%) 0.0621









Table 1 Patient (n – 141) Characteristics and Univariate
Analysis for Impact on Local Control (Continued)
Missing 24 (17%)
Median Overall Treatment Time (wks) 6.5 (4–9.7)
Radiation Dose (cGy) as Continous 6820 (6300–7264) 0.0367
≤66 Gy 45
> 66 Gy 96




Mean Follow-Up (month) 67.7 (0–239)
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and equally-weighted bilateral fields (p <0.04) were asso-
ciated with improved local control compared to bilateral
unequally weighted fields. Bilateral equally weighted fields
and unilateral fields were equally effective (p = 0.95).Local control
The 5-year actuarial local control rates were as follows:
T1a, 94%; T1b, 83%; T2a , 87%; T2b, 65%. The 10-year
actuarial local control rates were as follows: T1a, 89%;
T1b, 83%; T2a, 87%; T2b, 56% (Figure 2A). A total of
18 patients (12.7%) experienced local failures (Table 3).
The most common site of local recurrence was at the
initial site of the tumor (6) followed by elsewhere on
the true glottis but not at the original site of the pri-
mary location (4).Table 2 Multivariate Analysis for Impact on Local Control
Variables p-value HR 95% Confidence
(LL, UL)
Heavy Alcohol Use 0.0006
Current vs Never 0.0002 42.32 (5.7,309)
Former vs Never 0.4738 0.44 (0.05, 4.2)
Current vs Former 0.0016 116.00 (6.0, 1656)
Ant Commisure Inv (n vs y) 0.0940 0.21 (0.03, 1.31)
T Stage 0.024
2b vs 1a 0.0288 0.09 (0.01, 0.78)
2b vs 1b 0.2 5.76 (0.4, 83.4)
2b vs 2a 0.8 0.78 (0.12, 5)
Total Dose (continuous variable) 0.246 1.00 (0.99, 1.00)
Field Weighting/Arrangement 0.0569
Bilateral (Weighted) vs Non 0.0027 11.36 (1.32, 100)
Bilateral (Weighted) vs Unilateral 0.0422 10.70 (1.09, 100)
Bilateral (Non-weighted) vs
Unilateral
0.9473 0.93 (0.123, 7.11)
Subglottic Ext (n vs y) 0.7468 0.74 (0.117, 4.860)
Figure 2 Outcomes Including Local Control Rate (Figure 2A), Overall Survival (Figure 2B), and Cumulative Incidence of Death (Figure
2C) For Early Glottic Carcinoma.
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Table 3 Outcomes Post Radiation Therapy
Outcomes Post Radiotherapy n (% of total)
Local Recurrence 18 (12.8)
Only at Primary Site 6 (4)
Near Primary w/o Primary Site 8 (5.7)
Loco-Regional Recurrenc Including Primary 21 (14.9)
Nodal Failure Only w/o Primary 3 (2.1)
Salvage Surgery 20 (14.2)
Local Control with Salvage Sx 135 (95.7)
Salvage w/o Functional Larynx 11 (7.8)
Metastatic Failure 3 (2.1)
Lower Tracheal/Stomal 1 (0.007)
Lung 1 (0.007)
Other Primary Cancers 32 (22.7)
Most Common Site (Lung) 9 (6.3)
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functional larynx
Neck control rates were 97.9% with only 3 (2.1%) of the
patients failing in the regional lymph nodes. Similarly,
only 3 patients (2.1%) developed non-regional metastatic
failure: One in lower trachea and stoma, one in the lung,
and one was unknown. The most common form of sal-
vage therapy in 20 patients (14.2%) was total laryngect-
omy (8), laser cordotomy (6), or subtotal laryngectomy
(4). One patient had neither of these procedures and an-
other only had selective lymph node dissection. Six of
the patients that were salvaged underwent repeat salvage
therapy with either subtotal laryngectomy (1), total lar-
yngectomy (2) or some other procedure (3). The ultim-
ate local control rate of all patients including those that
were salvaged (12 out of 18 local failures) with surgery
was 95.7%. Of those that were salvaged 11 patients















missing 14 9.9Second tumors, overall survival, and cause specific
survival
Thirty-two patients (22.7%) developed second cancers:
the most common site was lung (9 patients) and prostate
(2 patients). The 5 and 10-year overall survival rates
were 77% and 50%, respectively (Figure 2B). The 5 and
10-year cumulative incidence of death were 3.9% and
5.5%, respectively (Figure 2C). A total of 62 deaths (44%)
occurred over the study interval. Recurrent larynx can-
cer as the cause of death occurred in only 5 patients
(3.5%). The rest died of non-larynx and non-second can-
cer related causes (26 patients), other cancers (9
patients), or of unknown causes (22 patients). During
the last follow-up, 78 patients (55.3%) were alive without
recurrent disease or were alive with recurrent disease (5
patients, 3.5%).Voice quality and toxicity outcomes
No patients experienced severe or fatal post radiation
complications. Pre and post-treatment symptoms are
shown in Table 4. 92% were noted to have baseline im-
pairment of voice prior to radiation. 73% of these patients
reported significant improvement, while 8.5% noted
chronic worsening of their voice. Chronic laryngeal edema
was noted in 26 patients (18.4%). Chronic dysphagia was
noted in 9 patients (6.4%). Only one patient (0.7%) devel-
oped severe laryngeal edema requiring a tracheostomy
(grade 4), and only one patient (0.7%) developed severe
dysphagia requiring long term tube feeding (grade 4).
Discusion
Our observed five-year LC for T1-T2a are excellent and
are better than or comparable to others [10]. The slight
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included all patients in our study, including three
patients with spindle cell variant histology. All three of
these patients failed locally suggesting the need for more
aggressive treatment in these patients. Another reason
could be due to the fact that we used a lower daily frac-
tional dose and avoided hyper-fractionationation. Des-
pite these subtle differences, we did not find total dose
or the fractional dose to be statistically significant on
MVA. This finding taken together with excellent out-
come for T1a patients suggests that current treatment
policies could be improved by reducing the total radi-
ation dose or avoiding hyper-fractionation in these
patients.
The relatively poor outcomes of patients with T2b
glottic carcinoma suggests that there are various degrees
of impaired mobility which are not adequately assessed
with existing methods. The impaired mobility is an indi-
cation of the extent of disease. Some of these patients
maybe on the verge of being T3 lesions, which would
suggest the need for more aggressive treatment strat-
egies such as hyper-fractionation or the use of concur-
rent chemo-radiotherapy. Trotti [13] et al. reported a
non-statistically significant improvement of 9% in LC at
five years (p= 0.11) for the use of hyper-fractionation in
T2N0 glottic cancer patients. Akimoto [14] et al.
reported that concurrent chemoradiotherapy had a non-
significant improvement in disease free survival of 91.8%
at 5 years compared to 70.9% no chemotherapy. Non-
oshita et al. [15] reported an impressive three-year local
control of 95.4% with the use of concurrent tegafur. An-
other treatment approach may involve some sort of lim-
ited surgical resection combined with neoadjuvant or
adjuvant chemoradiotherapy. This approach has yet to
be tested in a randomized trial.
Our analysis identified tumor stage (especially T2b),
concurrent heavy alcohol consumption, and field weight-
ing as factors that adversely impacted local control. An-
terior commissure involvement was also noted to be
statistically significant on MVA when we compared T2
patients with T1 patients. Tumor stage [3,7,9,10] and an-
terior commissure[3,8] involvement have also been
reported by others to predict for poor local control.
Other factors previously reported by others to poorly
impact local control on multivariate analysis include:
total dose (<65 Gy)[8]; overall treatment time[5,8] (> 41
days[10]); poorly differentiated histology[10]; smaller
fraction sizes[5,8,9] (< 2Gy vs > 2 Gy[6]); subglottic ex-
tension[6-8]; treatment delay (> 3 days)[2]; treatment
interruptions[2]; age, smaller field sizes[2,9]; gender[3,7];
higher beam energy[3]; pre-treatment hemoglobin levels
[4,7]; impaired vocal cord mobility[3,4,8]; and larger
tumor extent[3] (or tumor bulk[7]). We did not find
these factors to be statistically significant and could bedue to the fact that our patients were treated in a very
homogeneous manner. Most patients were treated to a
dose above 66 Gy, overall treatment time was kept short,
larger fraction sizes were used, and there were minimum
treatment delays and interruptions. Furthermore, most
patients were treated with 6 MV energy beams. It is un-
clear why heavy alcohol consumption during radiation
was significant for local control. One reason could be
due to the multi-organ effect of alcohol on the immune
system and the bone marrow system during radiation.
Another reason could be due to unknown biological
mechanisms leading to reduced radiation damage within
the cancer cells at the DNA level allowing cancer cells
to become more radioresistant. Future work should ad-
dress why concurrent heavy alcohol impacts local con-
trol in prospective studies.
Nearly all of our patients had baseline voice impair-
ment with 73% noting significant improvement and 8.5%
reported worsening after radiotherapy. Radiotherapy is
considered an acceptable treatment option and has simi-
lar [16] to slightly superior [17] patient reported voice
quality outcomes compared to CO2 laser excision, espe-
cially for T1 glottic carcinoma patients. However, radio-
therapy is more costly [17] and provides no additional
benefit in terms of differences in local control, laryngect-
omy free survival, or overall survival compared to C02
laser excision [17]. Radiation may be an option for those
unwilling to undergo surgery or for those with multiply
recurrent lesions after translaser oral excision. Future
health policies will need to address cost-effective care
for such patients through well controlled randomized
trials. Patients with T2 disease often require more exten-
sive surgical excision, thus the voice quality is better
with radiotherapy and open partial larygenctomy may be
more expensive [10].
There are several limitations. For one, our study is a
single institutional retrospective review spanning over
three decades. A direct comparison of radiotherapy with
alternative treatment strategies such as transoral CO2
laser excision or an open partial laryngectomy is better
made via a randomized controlled clinical trial. Another
limitation includes availability of only subjective mea-
sures of patient reported and physician reported voice
quality measures. Lastly, tumor volume and tumor
volume dosimetry is better captured in modern 3D treat-
ment techniques.Conclusion
Definitive radiotherapy provides excellent LC and CSS
for T1-T2a, N0 glottic SCC, with excellent voice preser-
vation outcomes and minimal long term toxicity. T2b
tumors have inferior outcomes, and alternative manage-
ment strategies should be pursued.
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